Alzheimer's Disease
Conditions
Keywords
Dementia
Brief summary
Primary Aim To determine whether; * Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment Secondary Aims To determine whether; * Donepezil has a significant positive or negative impact upon quality of life compared with placebo * whether there is a significant difference between Donepezil and placebo with respect to cognitive performance * the cost effectiveness of the pharmacological treatment for agitation
Interventions
DRUGDonepezil
Sponsors
Medical Research Council
Alzheimer's Society
Institute of Psychiatry, London
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score \>39 age \>39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate \-
Exclusion criteria
known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cohen Mansfield Agitation Inventory | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychiatric Inventory | — |
| Standardized Mini-Mental State Examination | — |
| Severe Impairment Battery | — |
| Clinical Global Impression of Severity/Change | — |
Countries
United Kingdom
Outcome results
None listed